-+ 0.00%
-+ 0.00%
-+ 0.00%

Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center

PUBT·07/29/2026 11:35:56
Listen to the news
Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center
  • Silexion Therapeutics initiated a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, activating the first site.
  • No clinical results have been presented; patient screening is expected to start in coming weeks, with first dosing anticipated next.
  • Study will test SIL204 with standard chemotherapy, aiming to support treatment of primary tumors while also targeting metastatic disease.
  • Trial design includes an initial safety run-in of about 18 patients, followed by a randomized cohort of about 166 patients as more sites join.
  • Additional sites in Israel and Germany are expected to come online in coming months, expanding the program’s execution footprint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.